Fantastic presentation at Festival of Biologics, congratulations Hilmar Ebersbach ! 👏 #festivalofbiologics
Excellent presentation from Hilmar Ebersbach (ImmunOs Therapeutics AG) ‘IOS-1002-A novel multi target therapeutic modulating 3 checkpoint pathways to activate both adaptive and innate immunity’ #festivalofbiologics #standingroomonly
👇 These are the top three news stories you need to read this week. 👇 #1: Gilead Sciences is bolstering its liver disease portfolio with the $4.3 billion acquisition of CymaBay Therapeutics, specifically for the primary biliary cholangitis (PBC) med seladelpar. #2: An experimental pill developed by KalVista Pharmaceuticals, Inc. succeeded in a Phase 3 trial, giving the drug a chance to become the first oral “on-demand” treatment for people with the rare swelling disorder hereditary angioedema. #3: The FDA has granted Fast Track designation to GSK’s novel antisense oligonucleotide (ASO) bepirovirsen to treat chronic hepatitis B (CHB).1 The drug was designed to specifically recognize the RNA used by hepatitis B virus (HBV) to replicate in infected liver cells. To read the full stories, please follow the links in the comments. #LifeSciencesNewsRoundUp #LifeSciences #ExecutiveSearch #FraserDove
You won't want to miss the upcoming webinar on the HEAL #Pain Therapeutics Development Program (#PTDP). Monday July 29, 2024 3:00 PM ET. This webinar will inform and provide participants with an opportunity to ask questions about PTDP and the #NIH funding announcement, RFA-NS-24-019 whose purpose is to support #preclinical optimization and development of safe, effective, and #nonaddictive small molecule and biologic therapeutics to treat pain. The goal of PTDP is to accelerate promising early therapeutic molecules and facilitate their readiness for the Early Phase Pain Investigation Clinical Network (EPPIC-Net) or other Phase II clinical studies. Link to register for the webinar: https://lnkd.in/g4ftETip
Ensure your #mRNA vaccine & therapeutic products analytical development success! 🚀 We hope to see you at the mRNA-Based Therapeutics Summit in Boston (July 29-31). Find out how Intertek experts can support your mRNA therapeutics development from early-stage characterization to late-stage development and commercialization! Please stop by our booth or contact us to schedule a meeting: Diogo Rodrigues and Mairita Ntoulovi. 🌍 Event: 4th Annual mRNA-Based Therapeutics Summit 📅 When: July 29-31, 2024 📍 Where: Boston, MA #mRNATherapeutics #mRNATherapeuticsSummit #mRNABasedTherapeuticsSummit
#MASHAdventCalendar Day 7 🎄 🎅 In the pursuit of effective treatments against #MASH, 2023 has witnessed promising developments of innovative therapeutics. Among the most advanced, are #Resmetirom (THR-beta from Madrigal Pharmaceuticals), #lanifibranor (pan-PPAR agonist from Inventiva Pharma), #obeticholicacid (FXR-agonist from Intercept Pharmaceuticals), and #semaglutide, a GLP-1 Receptor agonist from Novo Nordisk. Our recent poster presented by Cindy Serdjebi at American Association for the Study of Liver Diseases (AASLD) #TLM2023, in collaboration with Gubra (Michael Feigh), showcases results from the diet-induced obese MASH mouse model (#GAN DIO-MASH). It highlights that both lanifibranor and semaglutide significantly reduce steatosis, with lanifibranor also showing a remarkable reduction in fibrosis, including its thickness. Link to the poster : https://lnkd.in/e4x_ntF6
Scientist Product Analytics at Aurigene Pharmaceutical Services || Kemwell || SARC Syngene || Navya || Roha DC || IIT BHU
⏭ Here are some recent biopharma news stories ¹ ² ³ ⁴: Ø Bristol Myers’ leukemia drug Sprycel faces competition from generic versions in the US market Ø The US FDA rejected Novo Nordisk’s application for a new insulin product Ø The US Federal Trade Commission is suing CVS Caremark, Express Scripts, and Optum Rx over their drug price practices Ø AbbVie’s Humira lost more market share to biosimilars after being removed from CVS Caremark’s formularies Ø Pfizer and Evotec are collaborating on early discovery research for metabolic and infectious disease therapeutics Ø Roche recalled Susvimo’s ocular implant, insertion tool, and initial fill kit due to unsatisfactory test results Ø Novo Nordisk is investing $4.1 billion in a new fill/finish manufacturing facility in North Carolina. Source:1 https://lnkd.in/g7XdPHEf 2 https://lnkd.in/gQc9nbYQ 3,4 https://lnkd.in/gZYKFhs6 https://lnkd.in/gDgEyQ-t
In a press release and call to investors today, March 19, 2024, Design Therapeutics, Inc. provided an update on the progress of GeneTAC™ program in FA. “Our lead program in FA has a new drug product, DT-216P2, that we have designed to have an improved pharmacokinetic and injection site safety profile, which positions us to resume clinical development for this debilitating, degenerative, neuro-muscular genetic disease. This work builds on encouraging data in FA patients from our previous clinical trial." - Pratik Shah, Ph.D., chairperson and chief executive officer of Design Therapeutics Design is advancing DT-216P2 for FA, with plans to complete GLP studies by year-end 2024 to start patient trials in 2025. Click here to read the full press release: https://bit.ly/4cmnatS or to access the presentation to investors: https://bit.ly/3IHQhdB
#News 🎉 November 21, 2023 -- Connect Biopharma announced that it has entered into an exclusive license and collaboration agreement with Simcere to develop and commercialize Connect Biopharma’s rademikibart in Greater China. rademikibart (CBP-201) is an antibody designed to target IL-4Rα in development for the treatment of atopic dermatitis (AD) and asthma. Dupilumab, the IL-4Rα monoclonal antibody co-developed by Sanofi and Regeneration, has been launched in 2017. Dupilumab generated sales of €4.9bn in H1 2023 and it expected to across the €10bn market. 🔹 DDXCELL provides one-stop cell development service and related cell products to meet needs of drug research, including IL-4 and IL-13 stable cell lines. 👉 Click the link to know products: https://lnkd.in/g2_7s-QV #celllinedevelopment #cancertreatment #drugdiscovery #antibody #ADC #cytokines #asthma #atopicdermatitis
🌟 HIRC Insight Series 🌟 It is very encouraging to see the FDA's commitment to advancing treatments for rare diseases. This initiative marks a significant step forward in developing potentially life-changing therapies for patients with rare conditions. The next step is getting these treatments to the patients who need them. HIRC's new research with payers and specialty pharmacies assists manufacturers’ commercialization and market access efforts pertaining to rare disease portfolios. For more information visit: https://lnkd.in/gzUDFA4j #HIRCInsightSeries #HIRC #RareDisease #FDA #ClinicalTrials #STARTProgram #InnovativeTherapies #HealthcareAdvancement #Pharma #PharmaTrends #Pharmaceuticals #PharmaIndustry #PharmaNews #PharmaData #PharmaResearch #Healthcare #LifeSciences #Specialtypharmacy #Specialtypharmaceuticals #Orphandrugs #Genetherapy
On May 29, 2024, FDA notified selected participants of their acceptance into the Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program: https://lnkd.in/eFNrXnCV Announced in September 2023, the pilot is an FDA initiative to help further accelerate the development of novel drug and biological products for rare diseases.
With nearly 7,000 rare diseases affecting over 30 million Americans, the FDA's new START Pilot Program will be pivotal for the future treatment of these diseases and improving the lives of patients. Looking to gain insights on market access for rare diseases? HIRC's research with payers and specialty pharmacies supports manufacturers in commercialization and market access efforts. Click here: https://lnkd.in/erYKHcqf #HIRCInsightSeries #HIRC #RareDiseases #FDA #ClinicalTrials #STARTProgram #InnovativeTherapies #HealthcareAdvancement #Pharma #PharmaTrends #Pharmaceuticals #PharmaIndustry #PharmaNews #PharmaData #PharmaResearch #Healthcare #LifeSciences #Specialtypharmacy #Specialtypharmaceuticals #Orphandrugs #Genetherapy
On May 29, 2024, FDA notified selected participants of their acceptance into the Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program: https://lnkd.in/eFNrXnCV Announced in September 2023, the pilot is an FDA initiative to help further accelerate the development of novel drug and biological products for rare diseases.
[Clinical Trials] Applied Therapeutics, Inc. reports phase 3 trial results of AT-007 in SORD deficiency showing reduced sorbitol levels and improved patient-reported outcomes https://lnkd.in/gg96b8w6 CSL Behring B.V. and ABIONYX Pharma's CSL112 fails to meet endpoint in phase 3 AMI trial https://lnkd.in/geXfwXKK Tonix Pharmaceuticals' phase 3 trial of Tonmya achieves primary endpoint in fibromyalgia with reductions in pain and improvements in sleep and fatigue https://lnkd.in/ggYnsuyc Corcept Therapeutics' phase 4 trial of Korlym identifies hypercortisolism in 24% of Cushing's syndrome patients https://lnkd.in/gcXUpvw6 [Deals] Kelonia Therapeutics enters strategic collaboration with and Xyphos Biosciences for oncology CAR-T therapy candidate for $875 M https://lnkd.in/gF3YSD4Q ReCode Therapeutics and Intellia Therapeutics, Inc. sign strategic collaboration to advance gene editing therapy candidate for cystic fibrosis https://lnkd.in/gVrnsA94 Harrow and Apotex Inc. sign license agreement granting Canadian rights to market VERKAZIA for Vernal Keratoconjunctivitis and 4 more ophthalmic drugs https://lnkd.in/gKyvwvgk
Congratulations Hilmar and ImmunoTherapitics